EKTAF
Undervalued by 9.8% based on the discounted cash flow analysis.
Market cap | $1.91 Billion |
---|---|
Enterprise Value | $6.89 Billion |
Dividend Yield | $0.25 (5.01%) |
Earnings per Share | $0.62 |
Beta | 1.03 |
Outstanding Shares | 382,000,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 66.75 |
---|---|
PEG | 131.65 |
Price to Sales | 0.11 |
Price to Book Ratio | 0.23 |
Enterprise Value to Revenue | 0.39 |
Enterprise Value to EBIT | 7.78 |
Enterprise Value to Net Income | 25 |
Total Debt to Enterprise | 1.12 |
Debt to Equity | 0.85 |
No data
No data
Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology in...